Skip to main content
    Z

    Zai Lab Ltd (ZLAB)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $23.47
    -1.13 (-4.59%)

    Market Cap: $3.07B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Zai Lab Ltd (ZLAB) Earnings: Report Dates and Results

    Updated Nov 5, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    In the quarter ended Sep 30, 2026, Zai Lab reported EPS of -$0.41, above the -$0.59 estimate. It beat the EPS estimate in 3 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    53%(19/36)
    Avg Surprise
    +0.23%
    Streak
    2 Q

    Upcoming Estimates

    Report date not yet scheduledPeriod ending Dec 31, 2026
    EPS Consensus-$0.06
    Range-$0.06 - -$0.06
    4 analysts
    Revenue Consensus
    $105.62M
    Range$99.41M - $110.94M
    4 analysts
    Report date not yet scheduledPeriod ending Mar 31, 2027
    EPS Consensus-$0.44
    Range-$0.47 - -$0.40
    2 analysts
    EPS Revisions
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.59+26.3%
    60d ago-$0.53+17.9%
    30d ago-$0.53+17.9%
    7d ago-$0.53+17.9%
    Current-$0.44
    Revenue Consensus
    $112.90M
    Range$112.90M - $112.90M
    1 analysts

    Next Report

    ZLAB's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.

    ZLAB Earnings Call

    The latest ZLAB earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 36 quarters below that had an estimate, ZLAB beat 19, missed 16 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $108.21M, down 6.8% from $116.09M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.41-$0.59-$0.67 - -$0.50+30.51%BeatN/A62 up, 3 downNov 5, 2026$108.21M
    Jun 30, 2026-$0.46-$0.66-$0.99 - -$0.58+30.30%BeatN/A60 up, 4 downAug 6, 2026$106.31M
    Mar 31, 2026-$0.46-$0.29N/A-58.13%MissN/A50 up, 3 downMay 7, 2026$99.61M
    Dec 31, 2025-$0.46-$0.44-$0.75 - -$0.22-4.55%MissN/A61 up, 2 downFeb 26, 2026$127.60M
    Sep 30, 2025-$0.33-$0.29-$0.37 - -$0.21-13.79%MissN/A60 up, 2 downNov 6, 2025$116.09M
    Jun 30, 2025-$0.37-$0.37-$0.56 - -$0.350.00%In lineN/A61 up, 1 downAug 7, 2025$109.98M
    Mar 31, 2025-$0.45-$0.55-$0.69 - -$0.47+18.18%BeatN/A5N/AMay 8, 2025$106.49M
    Dec 31, 2024-$0.80-$0.63-$0.72 - -$0.48-26.32%MissN/A52 up, 0 downFeb 27, 2025$109.07M
    Sep 30, 2024-$0.42-$0.78-$0.90 - -$0.68+46.15%BeatN/A61 up, 0 downNov 12, 2024$102.27M
    Jun 30, 2024-$0.82-$0.73-$0.85 - -$0.59-12.33%MissN/A60 up, 0 downAug 6, 2024$100.50M
    Mar 31, 2024-$0.50-$0.92-$1.09 - -$0.75+45.65%BeatN/A61 up, 0 downMay 8, 2024$87.15M
    Dec 31, 2023-$0.98-$0.87-$0.97 - -$0.78-12.64%MissN/A60 up, 0 downFeb 27, 2024$65.83M
    Sep 30, 2023-$0.71-$1.03-$1.25 - -$0.71+31.07%BeatN/A60 up, 2 downNov 7, 2023$69.23M
    Jun 30, 2023-$1.25-$0.81-$1.04 - -$0.66-54.32%MissN/A50 up, 0 downAug 7, 2023$68.86M
    Mar 31, 2023-$0.51-$0.97-$1.05 - -$0.86+47.42%BeatN/A51 up, 0 downMay 9, 2023$62.80M
    Dec 31, 2022-$0.65-$1.11-$1.33 - -$1.01+41.44%BeatN/A50 up, 0 downFeb 28, 2023$62.60M
    Sep 30, 2022-$1.68-$1.25-$1.68 - -$0.20-34.40%MissN/A50 up, 0 downNov 9, 2022$57.54M
    Jun 30, 2022-$1.44-$1.07-$1.44 - -$0.93-34.58%MissN/A40 up, 0 downAug 9, 2022$48.18M
    Mar 31, 2022-$0.86-$1.23N/A+30.08%BeatN/A40 up, 0 downMay 10, 2022$46.72M
    Dec 31, 2021-$2.17-$1.33N/A-63.16%MissN/AN/AN/AMar 1, 2022$44.17M
    Sep 30, 2021-$1.01-$1.27-$1.74 - -$1.01+20.47%BeatN/A50 up, 0 downNov 9, 2021$43.10M
    Jun 30, 2021-$1.76-$1.39-$1.76 - -$1.33-26.62%MissN/A40 up, 0 downAug 9, 2021$36.94M
    Mar 31, 2021-$2.64-$2.30-$2.30 - -$0.86-14.78%MissN/A2N/AMay 10, 2021$20.10M
    Dec 31, 2020-$0.40-$0.99N/A+59.78%BeatN/AN/AN/AMar 1, 2021$15.09M
    Sep 30, 2020-$0.40-$0.40N/A+0.45%BeatN/AN/AN/ADec 2, 2020$14.65M
    Jun 30, 2020-$0.67-$0.99N/A+32.32%BeatN/AN/AN/AAug 13, 2020$10.99M
    Mar 31, 2020-$0.99-$0.99N/A+0.01%BeatN/AN/AN/AJun 3, 2020$8.22M
    Dec 31, 2019-$0.68-$0.60N/A-13.33%MissN/A1N/AJan 21, 2020$4.65M
    Sep 30, 2019-$0.60-$0.60N/A+0.78%BeatN/AN/AN/ANov 27, 2019$4.92M
    Jun 30, 2019-$0.43-$0.67N/A+35.82%BeatN/AN/AN/ASep 3, 2019$1.71M
    Mar 31, 2019-$0.67-$0.44N/A-52.66%MissN/AN/AN/AMay 29, 2019$1.71M
    Dec 31, 2018-$0.68-$0.45N/A-51.11%MissN/AN/AN/AMar 7, 2019$129452
    Sep 30, 2018-$0.33-$0.40N/A+17.50%BeatN/AN/AN/ANov 28, 2018$64726
    Jun 30, 2018-$0.26-$0.38N/A+31.58%BeatN/AN/AN/AAug 30, 2018N/A
    Mar 31, 2018-$0.25-$0.17N/A-47.06%MissN/AN/AN/AMay 2, 2018N/A
    Dec 31, 2017-$3.95N/AN/AN/AN/AN/AN/AN/ADec 31, 2017N/A
    Sep 30, 2017-$0.21-$0.23N/A+8.70%BeatN/AN/AN/ANov 15, 2017N/A
    Jun 30, 2017-$0.75N/AN/AN/AN/AN/AN/AN/ASep 21, 2017N/A
    Mar 31, 2017-$11.49N/AN/AN/AN/AN/AN/AN/AMar 31, 2017N/A
    Dec 31, 2016-$0.76N/AN/AN/AN/AN/AN/AN/AMar 30, 2017N/A
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$1.61, after -$2.54 the year before. It was -$1.00 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$1.61N/A
    Dec 31, 2024-$2.54N/A
    Dec 31, 2023-$3.45N/A
    Dec 31, 2022-$4.63N/A
    Dec 31, 2021-$7.58N/A
    Dec 31, 2020-$2.46N/A
    Dec 31, 2019-$2.38N/A
    Dec 31, 2018-$2.48N/A
    Dec 31, 2017-$23.20N/A
    Dec 31, 2016-$1.00N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,000 words across 12 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20263,99512
    2026Q2Jun 30, 20264,45612
    2026Q1Mar 31, 20263,69511
    2025Q4Dec 31, 20255,95513
    2025Q3Sep 30, 20256,37513
    2025Q2Jun 30, 20256,88712
    2025Q1Mar 31, 20257,23716
    2024Q4Dec 31, 20247,36013

    2026Q3 Earnings Call

    Opening remarks

    Christine Chiou Senior Vice President of Investor Relations Thank you, operator. Hello and welcome, everyone. Today's earnings call will be led by Dr. Samantha Du, Zai Lab's Founder, CEO, and Chairperson. She will be joined by Dr. Rafael Amado, President and Head of Global Research and Development, and Dr. Yajing Chen, Chief Financial Officer. Dr. Shan He, our Chief Business Officer, and Dr. Yizhe Wang, our Operating Partner, will also be available to answer questions during the Q&A portion of the call. As a reminder, during today's call, we will be making certain forward-looking statements based on our current expectations. These statements are subject to numerous risks and uncertainties that may cause actual results to differ materially from what we expect due to a variety of factors, including those discussed in our SEC filings. We will also refer to adjusted loss from operations, which is a non-GAAP financial measure. Please refer to our earnings release furnished with the SEC on November 5, 2026, for additional information on this non-GAAP financial measure. At this time, it is my pleasure to turn the call over to Dr. Samantha Du.

    Samantha Du Founder, CEO, and Chairperson Thanks, Christine. Good morning and good evening, everyone. We're entering one of the most important periods in Zai Lab's history. I founded Zai Lab to discover and develop innovative medicines for patients around the world. We have spent years building the talent, scientific capabilities, and infrastructure to make that possible. With zoci advancing toward a potential U.S. BLA submission next year, that vision is within our reach. Our first-line ESMO data strengthened our confidence that zoci can become the ADC backbone in small cell lung cancer. We are advancing the zoci-IO doublet into a global phase III study and building on it through our T-cell engager collaborations with Amgen and BI. The next two years are pivotal. By year-end, we expect three registrational studies underway across small cell lung cancer and neuroendocrine carcinomas. In 2027, we anticipate two registrational results and our first potential U.S. BLA submission, positioning us for a U.S. launch as early as 2028. This would be a defining achievement for our company. Our recent $250 million financing further strengthens our ability to deliver on the plan. Our ambition extends well beyond zoci. Next week, we will present the first clinical data for ZL-1503, our internally developed bispecific for atopic dermatitis. We also expect three additional oncology and immunology assets in clinical development next year. Meanwhile, we continued to strengthen our China commercial business. Net product revenue grew 2% sequentially, and our China business remained profitable. This performance is consistent with the stabilization we outlined on our second quarter call.

    Frequently Asked Questions About ZLAB

    Did ZLAB beat earnings estimates last quarter?

    Yes. Zai Lab reported EPS of -$0.41 for the quarter ended Sep 30, 2026, above the -$0.59 estimate, a 30.51% surprise.

    What EPS do analysts expect from ZLAB next quarter?

    The consensus EPS estimate for Zai Lab for the quarter ending Dec 31, 2026 is -$0.06 from 4 analysts, with estimates from -$0.06 to -$0.06.

    How often does ZLAB beat earnings estimates?

    Zai Lab beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of -2.97%.